Tobias Max Philipp Hartwich

6PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 15, 2026
Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer.

|Aug 27, 2025
Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody-Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas.

Niccolò G Santin, Namrata Sethi, Stefania Bellone

|Apr 29, 2025
Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma.

Michelle Greenman, Cem Demirkiran, Stefania Bellone

|Jan 25, 2025
SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer.

Ziyan Jiang, Fangfang Bi, Zhiping Ge

|Sep 07, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.

Levent Mutlu, Diego D Manavella, Stefania Bellone

|Oct 27, 2022
Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.

Ryan D Chow, Tai Michaels, Stefania Bellone

Pageof 1

Frequent Collaborators

5 joint publications

Stefania Bellone

5 joint publications

Alessandro D Santin

4 joint publications

Cem Demirkiran

3 joint publications

Namrata Sethi